{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:17:50Z","timestamp":1787998670758,"version":"build-2784847793"},"reference-count":54,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023452","name":"Hanarth Fonds","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023452","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Gastric cancer remains associated with a high mortality, since patients often present with advanced-stage disease such as peritoneal metastases. Treatment options in this setting are limited and mainly consist of palliative systemic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This systematic review aims to summarize emerging therapeutic strategies for patients with peritoneally metastasized gastric cancer in relation to response, toxicity, and survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A search was performed in PubMed, EMBASE, and Cochrane database until December 8, 2023. Studies were eligible if they prospectively investigated any form of cancer treatment in adult patients with peritoneally metastasized gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 25 articles were retrieved from 9 different countries, investigating systemic therapy, intraperitoneal therapy (IP), hyperthermic intraperitoneal chemotherapy (HIPEC) with or without cytoreductive surgery (CRS), and pressurized intraperitoneal aerosol chemotherapy (PIPAC). CRS-HIPEC followed by early postoperative intraperitoneal chemotherapy (EPIC) showed high complication rates and patient drop-out. Median overall survival (OS) ranged from 6.5 to 7.4\u2009months with systemic chemotherapy, 13.0 to 23.9\u2009months with IP chemotherapy, 6.8 to 13.0\u2009months after PIPAC, 11.0 to 19.0\u2009months with CRS-HIPEC, and 9.9\u2009months in elderly with HIPEC alone. Notably, patients with a Peritoneal Cancer Index \u226520 showed median OS \u226513.0\u2009months with IP chemotherapy or HIPEC without CRS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Few prospective trials are conducted in patients with peritoneally metastasized gastric cancer. Although IP chemotherapy and CRS-HIPEC show encouraging results in selected cohorts, especially in Asia, current evidence from randomized studies is limited. Further prospective trials are needed to clarify their role alongside the current systemic therapy, including immunotherapy and targeted therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf219","type":"journal-article","created":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T11:58:10Z","timestamp":1754049490000},"source":"Crossref","is-referenced-by-count":7,"title":["Emerging treatment modalities for gastric cancer with peritoneal metastases: a systematic review"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0911-8905","authenticated-orcid":false,"given":"Marion Wilhelmina","family":"Tops-Welten","sequence":"first","affiliation":[{"name":"Department of Oncology, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]},{"name":"GROW School for Oncology and Developmental Biology, Maastricht University , Maastricht 6229 ER,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9441-4154","authenticated-orcid":false,"given":"Laskarina Jaklien Konstantina","family":"Galanos","sequence":"additional","affiliation":[{"name":"GROW School for Oncology and Developmental Biology, Maastricht University , Maastricht 6229 ER,","place":["the Netherlands"]},{"name":"Department of Surgery, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9358-1996","authenticated-orcid":false,"given":"Geert-Jan","family":"Creemers","sequence":"additional","affiliation":[{"name":"Department of Oncology, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9483-1520","authenticated-orcid":false,"given":"Misha Derek Philip","family":"Luyer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]},{"name":"Department of Electrical Engineering, Eindhoven University of Technology (TU\/e) , Eindhoven 5612 AP,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3491-4268","authenticated-orcid":false,"given":"Ignace Hubertus Johannes Theodorus","family":"De Hingh","sequence":"additional","affiliation":[{"name":"GROW School for Oncology and Developmental Biology, Maastricht University , Maastricht 6229 ER,","place":["the Netherlands"]},{"name":"Department of Surgery, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9513-7126","authenticated-orcid":false,"given":"Irene Elisabeth Gerarda","family":"van Hellemond","sequence":"additional","affiliation":[{"name":"Department of Oncology, Catharina Cancer Institute, Catharina Hospital , Eindhoven 5623 EJ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025102304261165400_oyaf219-B1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2025102304261165400_oyaf219-B2","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s10120-021-01160-1","article-title":"Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort","volume":"24","author":"Koemans","year":"2021","journal-title":"Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5230\/jgc.2021.21.e12","article-title":"Treatment modality based survival in gastric carcinoma patients with stand-alone peritoneal metastasis: a case-control study","volume":"21","author":"Jeong","year":"2021","journal-title":"J Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B4","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1002\/ijc.34780","article-title":"Peritoneal metastases from gastric cancer in a nationwide cohort: incidence, treatment and survival","volume":"154","author":"Rijken","year":"2024","journal-title":"Int J Cancer"},{"key":"2025102304261165400_oyaf219-B5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s10120-016-0662-9","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis","volume":"20","author":"Kobayashi","year":"2017","journal-title":"Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s11864-018-0563-8","article-title":"Metastatic colorectal cancer to the peritoneum: current treatment options","volume":"19","author":"Vassos","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"2025102304261165400_oyaf219-B7","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1245\/s10434-008-9966-2","article-title":"8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer","volume":"15","author":"Verwaal","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"2025102304261165400_oyaf219-B8","doi-asserted-by":"publisher","first-page":"1758835918777036","DOI":"10.1177\/1758835918777036","article-title":"Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis","volume":"10","author":"Graversen","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2025102304261165400_oyaf219-B9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13048-019-0509-1","article-title":"The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: the meta-analysis","volume":"12","author":"Zhang","year":"2019","journal-title":"J Ovarian Res"},{"key":"2025102304261165400_oyaf219-B10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","article-title":"Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial","volume":"2","author":"Shitara","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025102304261165400_oyaf219-B11","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10120-020-01043-x","article-title":"Randomized phase II\/III study of 5-fluorouracil\/l-leucovorin versus 5-fluorouracil\/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108\/WJOG7312G)","volume":"23","author":"Nakajima","year":"2020","journal-title":"Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B12","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1200\/JCO.2018.77.8613","article-title":"Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial","volume":"36","author":"Ishigami","year":"2018","journal-title":"J Clin Oncol"},{"key":"2025102304261165400_oyaf219-B13","first-page":"211","article-title":"Efficacy of conversion surgery after neoadjuvant intraperitoneal-systemic chemotherapy in treating peritoneal metastasis of gastric cancer","volume":"26","author":"Li","year":"2021","journal-title":"J Buon"},{"key":"2025102304261165400_oyaf219-B14","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.21873\/anticanres.12945","article-title":"Intraperitoneal and systemic chemotherapy for patients with gastric cancer with peritoneal metastasis: a phase II trial","volume":"38","author":"Shinkai","year":"2018","journal-title":"Anticancer Res"},{"key":"2025102304261165400_oyaf219-B15","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.1002\/cncr.28204","article-title":"A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis","volume":"119","author":"Yamaguchi","year":"2013","journal-title":"Cancer"},{"key":"2025102304261165400_oyaf219-B16","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1007\/s11605-012-2059-3","article-title":"Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"16","author":"Imano","year":"2012","journal-title":"J Gastrointest Surg"},{"key":"2025102304261165400_oyaf219-B17","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1007\/s10120-017-0710-0","article-title":"Phase I\/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis","volume":"20","author":"Cho","year":"2017","journal-title":"Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B18","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1245\/s10434-022-11582-5","article-title":"Safety and efficacy of intraperitoneal paclitaxel plus intravenous fluorouracil, leucovorin, and oxaliplatin (FOLFOX) for gastric cancer with peritoneal metastasis","volume":"29","author":"Kang","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"2025102304261165400_oyaf219-B19","doi-asserted-by":"publisher","first-page":"20190035","DOI":"10.1515\/pp-2019-0035","article-title":"Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries","volume":"5","author":"Lo Dico","year":"2020","journal-title":"Pleura Peritoneum"},{"key":"2025102304261165400_oyaf219-B20","first-page":"4071","article-title":"A preliminary study of single intraperitoneal administration of paclitaxel followed by sequential systemic chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal metastasis","volume":"32","author":"Imano","year":"2012","journal-title":"Anticancer Res"},{"key":"2025102304261165400_oyaf219-B21","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00280-010-1272-6","article-title":"Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding","volume":"67","author":"Choi","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025102304261165400_oyaf219-B22","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1200\/JCO.22.02867","article-title":"Effect of hyperthermic intraperitoneal chemotherapy on cytoreductive surgery in gastric cancer with synchronous peritoneal metastases: the phase III GASTRIPEC-I trial","volume":"42","author":"Rau","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025102304261165400_oyaf219-B23","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1245\/s10434-011-1631-5","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial","volume":"18","author":"Yang","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2025102304261165400_oyaf219-B24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1186\/s12885-017-3730-6","article-title":"Cytoreductive surgery and hyperthermic intra-operative peritoneal chemotherapy with cisplatin for gastric peritoneal carcinomatosis monocentric phase-2 nonrandomized prospective clinical trial","volume":"17","author":"Topal","year":"2017","journal-title":"BMC Cancer"},{"key":"2025102304261165400_oyaf219-B25","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.12998\/wjcc.v10.i5.1498","article-title":"Elemene-containing hyperthermic intraperitoneal chemotherapy combined with chemotherapy for elderly patients with peritoneal metastatic advanced gastric cancer","volume":"10","author":"Chen","year":"2022","journal-title":"World J Clin Cases"},{"key":"2025102304261165400_oyaf219-B26","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.3390\/cancers11111715","article-title":"Conversion surgery with HIPEC for peritoneal oligometastatic gastric cancer","volume":"11","author":"Mielko","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2025102304261165400_oyaf219-B27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3109\/0284186X.2012.702925","article-title":"Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy","volume":"52","author":"Hultman","year":"2013","journal-title":"Acta Oncol"},{"key":"2025102304261165400_oyaf219-B28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3109\/0284186X.2011.594809","article-title":"Costs and clinical outcome of neoadjuvant systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from gastric cancer","volume":"51","author":"Hultman","year":"2012","journal-title":"Acta Oncol"},{"key":"2025102304261165400_oyaf219-B29","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5230\/jgc.2018.18.e32","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as treatment options for peritoneal metastasis of advanced gastric cancer","volume":"18","author":"Kim","year":"2018","journal-title":"J Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1515\/pp-2016-0017","article-title":"Bidirectional chemotherapy in gastric cancer with peritoneal metastasis combining intravenous XELOX with intraperitoneal chemotherapy with low-dose cisplatin and doxorubicin administered as a pressurized aerosol: an open-label, phase-2 study (PIPAC-GA2)","volume":"1","author":"Khomyakov","year":"2016","journal-title":"Pleura Peritoneum"},{"key":"2025102304261165400_oyaf219-B31","doi-asserted-by":"publisher","first-page":"1758835919846402","DOI":"10.1177\/1758835919846402","article-title":"Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C\/D) in patients with gastric cancer and peritoneal metastasis: a phase II study","volume":"11","author":"Struller","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"2025102304261165400_oyaf219-B32","doi-asserted-by":"publisher","first-page":"379","DOI":"10.5230\/jgc.2018.18.e37","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in gastric cancer patients with peritoneal metastasis (PM): results of a single-center experience and register study","volume":"18","author":"Gockel","year":"2018","journal-title":"J Gastric Cancer"},{"key":"2025102304261165400_oyaf219-B33","doi-asserted-by":"publisher","first-page":"2743985","DOI":"10.1155\/2018\/2743985","article-title":"Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a registry study","volume":"2018","author":"Kurtz","year":"2018","journal-title":"Gastroenterol Res Pract"},{"key":"2025102304261165400_oyaf219-B34","author":"Cui","year":"2017"},{"key":"2025102304261165400_oyaf219-B35","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1186\/s12885-019-5640-2","article-title":"Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II)","volume":"19","author":"Koemans","year":"2019","journal-title":"BMC Cancer"},{"key":"2025102304261165400_oyaf219-B36","author":"Li","year":"2016"},{"key":"2025102304261165400_oyaf219-B37","author":"Han","year":"2022"},{"key":"2025102304261165400_oyaf219-B38","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.2217\/fon-2021-1414","article-title":"A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis","volume":"18","author":"Lu","year":"2022","journal-title":"Future Oncol"},{"key":"2025102304261165400_oyaf219-B39","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.2217\/fon-2022-0738","article-title":"Sintilimab combined neoadjuvant intraperitoneal and systemic chemotherapy in gastric cancer with peritoneal metastasis","volume":"19","author":"Yuan","year":"2023","journal-title":"Future Oncol"},{"key":"2025102304261165400_oyaf219-B40","author":"Mathijssen","year":"2022"},{"key":"2025102304261165400_oyaf219-B41","doi-asserted-by":"publisher","first-page":"e1744","DOI":"10.1590\/0102-672020230026e1744","article-title":"Intraperitoneal chemotherapy for gastric cancer with peritoneal carcinomatosis: study protocol of a phase ii trial","volume":"36","author":"Ramos","year":"2023","journal-title":"Arq Bras Cir Dig"},{"key":"2025102304261165400_oyaf219-B42","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1186\/s12885-023-11549-z","article-title":"Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in combination with FOLFOX chemotherapy as a first-line treatment for gastric cancer patients with peritoneal metastases: single-arm phase II study","volume":"23","author":"Luksta","year":"2023","journal-title":"BMC Cancer"},{"key":"2025102304261165400_oyaf219-B43","doi-asserted-by":"publisher","first-page":"e067691","DOI":"10.1136\/bmjopen-2022-067691","article-title":"Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity","volume":"13","author":"Lang","year":"2023","journal-title":"BMJ Open"},{"key":"2025102304261165400_oyaf219-B44","doi-asserted-by":"publisher","first-page":"20180116","DOI":"10.1515\/pp-2018-0116","article-title":"PIPAC EstoK 01: Pressurized IntraPeritoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C\/D) in gastric peritoneal metastasis: a randomized and multicenter phase II study","volume":"3","author":"Eveno","year":"2018","journal-title":"Pleura Peritoneum"},{"key":"2025102304261165400_oyaf219-B45","doi-asserted-by":"publisher","first-page":"569","DOI":"10.4251\/wjgo.v12.i5.569","article-title":"Gastric cancer with peritoneal metastases: efficiency of standard treatment methods","volume":"12","author":"Yarema","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"2025102304261165400_oyaf219-B46","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.3390\/jcm10214882","article-title":"The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival","volume":"10","author":"Rijken","year":"2021","journal-title":"J Clin Med"},{"key":"2025102304261165400_oyaf219-B47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [published correction appears in Lancet. 2010 Oct 16; 376(9749):1302]","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"2025102304261165400_oyaf219-B48","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"2025102304261165400_oyaf219-B49","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s40265-022-01828-7","article-title":"Intraperitoneal chemotherapy for unresectable peritoneal surface malignancies","volume":"83","author":"Guchelaar","year":"2023","journal-title":"Drugs"},{"key":"2025102304261165400_oyaf219-B50","doi-asserted-by":"publisher","first-page":"F433","DOI":"10.1152\/ajprenal.00313.2004","article-title":"The transport barrier in intraperitoneal therapy","volume":"288","author":"Flessner","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025102304261165400_oyaf219-B51","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/bjs5.50179","article-title":"Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy","volume":"3","author":"Hallam","year":"2019","journal-title":"BJS Open"},{"key":"2025102304261165400_oyaf219-B52","doi-asserted-by":"publisher","first-page":"20458","DOI":"10.1038\/s41598-023-47510-0","article-title":"Comparing patient reported abdominal pain between patients treated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC-OX) and primary colorectal cancer surgery","volume":"13","author":"van de Vlasakker","year":"2023","journal-title":"Sci Rep"},{"key":"2025102304261165400_oyaf219-B53","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.3390\/cancers15061777","article-title":"Gastric cancer with peritoneal metastases: current status and prospects for treatment","volume":"15","author":"Manzanedo","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2025102304261165400_oyaf219-B54","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1007\/s10120-019-00969-1","article-title":"The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis","volume":"22","author":"Rau","year":"2019","journal-title":"Gastric Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf219\/63961243\/oyaf219.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf219\/63961243\/oyaf219.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/9\/oyaf219\/63961243\/oyaf219.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T08:26:19Z","timestamp":1761207979000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf219\/8222739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf219","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,8,5]]},"article-number":"oyaf219"}}